Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFB | P00751 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.38 |
| ▸ | CD38 | P28907 | 1/20 | 0.38 |
| ▸ | CFD | P00746 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1178307 | 0.86 | CYP2A13 (0.43) | CFBP2RX7POLB | |
| SCHEMBL1178958 | 0.85 | GAA (0.46) | CFBTP53POLBGAATSHR | |
| SCHEMBL10014958 | 0.83 | TAAR1 (0.45) | CFBTP53GAATAAR1ADRA2A | |
| SCHEMBL8348698 | 0.83 | TAAR1 (0.34) | CFBTAAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL1178173 | 0.78 | CD38 (0.36) | CFBP2RX7CD38MAP4K1ADRA2A | |
| SCHEMBL1178947 | 0.77 | P2RX7 (0.45) | P2RX7 | |
| SCHEMBL14213775 | 0.76 | P2RX7 (0.38) | CFBP2RX7 | |
| SCHEMBL1178520 | 0.74 | TAAR1 (0.47) | CFBP2RX7CD38TP53GAA | |
| SCHEMBL3411857 | 0.74 | CFB (0.36) | CFBP2RX7CFDTAAR1MAP4K1 | |
| SCHEMBL1179180 | 0.74 | CYP2A13 (0.41) | CFBPOLBEGFRADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10251865-B2 | Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists | ALLERGAN, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| EP-3332782-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. (US) | 2018-06-13 | — | — | EP | disclosed |
| US-20180071259-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180071259-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20170079956-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. | 2017-03-23 | — | — | US | disclosed |
| US-20170079956-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. | 2017-03-23 | — | — | US | disclosed |
| US-9545394-B2 | Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists | ALLERGAN, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-9545394-B2 | Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists | ALLERGAN, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160158199-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. | 2016-06-09 | — | — | US | disclosed |
| US-20160158199-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. | 2016-06-09 | — | — | US | disclosed |
| US-20120041031-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC (US) | 2012-02-16 | — | — | US | disclosed |
| EP-2351561-A2 | Novel methods and compositions for alleviating pain | Allergan, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20110028523-A1 | Selective Alpha 2B/2C Agonists | ALLERGAN, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-20110028523-A1 | Selective Alpha 2B/2C Agonists | ALLERGAN, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-20110028523-A1 | Selective Alpha 2B/2C Agonists | ALLERGAN, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| WO-2011014332-A1 | SELECTIVE ALPHA 2B/2C AGONISTS | ALLERGAN, INC. (US) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011014332-A1 | SELECTIVE ALPHA 2B/2C AGONISTS | ALLERGAN, INC. (US) | 2011-02-03 | — | — | WO | disclosed |
| US-7345065-B2 | Methods and compositions for alleviating pain | ALLERGAN, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345065-B2 | Methods and compositions for alleviating pain | ALLERGAN, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| WO-2003099289-A2 | COMPOSITIONS AND THEIR USES FOR ALLEVIATING PAIN | ALLERGAN, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041031-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ADRA2B, ADRB2, ADRA2A | CFB 2236/4885P2RX7 291/4885CD38 874/4885 |
| US-20180071259-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ADRA2B, ADRB2, ADRA2A | CFB 2333/4885P2RX7 305/4885CD38 872/4885 |
| US-20110028523-A1 | Selective Alpha 2B/2C Agonists | ADRA2C, ADRA2B, ADRB2 | CFB 3527/4885P2RX7 123/4885CD38 1384/4885 |
| US-20160158199-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ADRA2B, ADRB2, ADRA2A | CFB 2333/4885P2RX7 305/4885CD38 872/4885 |
| US-20170079956-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ADRA2B, ADRB2, ADRA2A | CFB 2261/4885P2RX7 301/4885CD38 888/4885 |
| US-10251865-B2 | Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists | ADRA2B, ADRB2, ADRA2A | CFB 2333/4885P2RX7 305/4885CD38 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.